Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 52-Week High - Time to Buy?

Key Points

• Supernus Pharmaceuticals shares reached a new 52-week high of $46.87, reflecting a significant increase in trading activity with 179,206 shares exchanged.
• Brokerages have adjusted their ratings for Supernus, with Zacks upgrading it to a strong-buy and a consensus target price of $43.00.
• Recent insider transactions revealed significant stock sales, with the CFO selling 11,780 shares, indicating a 90.43% decrease in their ownership of the company.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $46.82 and last traded at $46.87, with a volume of 179206 shares changing hands. The stock had previously closed at $46.04.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on SUPN. Zacks Research upgraded Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 17th. Cantor Fitzgerald upped their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Piper Sandler upped their price objective on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a report on Friday, August 29th. Finally, Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $43.00.

Supernus Pharmaceuticals Price Performance

The business has a 50 day simple moving average of $40.93 and a 200 day simple moving average of $35.18. The company has a market capitalization of $2.65 billion, a price-to-earnings ratio of 41.07 and a beta of 0.79.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 14,000 shares of the company's stock in a transaction on Monday, August 25th. The stock was sold at an average price of $44.51, for a total transaction of $623,140.00. Following the transaction, the senior vice president directly owned 15,496 shares in the company, valued at $689,726.96. This represents a 47.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Timothy C. Dec sold 11,780 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $44.49, for a total value of $524,092.20. Following the transaction, the chief financial officer owned 1,246 shares in the company, valued at $55,434.54. This trade represents a 90.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 246,506 shares of company stock valued at $10,696,144 over the last ninety days. 8.80% of the stock is owned by insiders.

Institutional Trading of Supernus Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Supernus Pharmaceuticals by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock valued at $1,033,000 after acquiring an additional 1,083 shares in the last quarter. Two Sigma Advisers LP raised its stake in shares of Supernus Pharmaceuticals by 14.7% in the fourth quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock valued at $282,000 after acquiring an additional 1,000 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Supernus Pharmaceuticals by 3.2% in the first quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock valued at $10,032,000 after acquiring an additional 9,590 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Supernus Pharmaceuticals by 63.6% in the first quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock valued at $579,000 after acquiring an additional 6,867 shares in the last quarter. Finally, Quantinno Capital Management LP raised its stake in shares of Supernus Pharmaceuticals by 11.5% in the fourth quarter. Quantinno Capital Management LP now owns 8,401 shares of the specialty pharmaceutical company's stock valued at $304,000 after acquiring an additional 864 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.